title: Ifosfamide in the treatment of lymphoma.
abstract: Currently, approximately 50% of patients with non-Hodgkin's lymphoma are eventually cured. Most patients who are cured reach a complete response after first-line chemotherapy, but a meaningful number of patients with partial response and those whose treatment fails or whose disease relapses can achieve a durable disease-free remission with effective salvage therapy. This usually involves multidrug intensive chemotherapy with or without bone marrow transplantation. Ifosfamide, an active drug in this setting, is a component of many of these salvage regimens. Some results with the combination of ifosfamide/etoposide, sometimes combined with mitoxantrone and/or cytarabine, are presented. Many relapsing lymphoma patients will require additional treatment after salvage chemotherapy, such as high-dose therapy with bone marrow transplantation, to realize a better long-term outcome.
authors.affiliation: Service d'Hématologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage; D016879:Salvage Therapy; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018906:Antineoplastic Agents, Alkylating; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007069:Ifosfamide; D011241:Prednisone